

# Lana Ganoci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9047471/publications.pdf>

Version: 2024-02-01

18  
papers

179  
citations

1307594

7  
h-index

1125743

13  
g-index

19  
all docs

19  
docs citations

19  
times ranked

294  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>ABCG2</i> gene polymorphisms as risk factors for atorvastatin adverse reactions: a caseâ€“control study. <i>Pharmacogenomics</i> , 2015, 16, 803-815.	1.3	32
2	Genetic polymorphisms of cytochrome P450 enzymes: <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP3A4</i>, and <i>CYP3A5</i> in the Croatian population. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 11-21.	0.6	27
3	Interaction between <i>ABCG2 421C>A</i> polymorphism and valproate in their effects on steadyâ€“state disposition of lamotrigine in adults with epilepsy. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2106-2119.	2.4	24
4	Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 513-520.	1.3	18
5	<i>CYP2D6 *6/*6</i> genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. <i>Pharmacogenomics</i> , 2016, 17, 1385-1389.	1.3	9
6	Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis. <i>European Psychiatry</i> , 2019, 61, 88-96.	0.2	9
7	ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110042.	4.8	9
8	INTEGRATION OF COMPLEMENTARY BIOMARKERS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS: RESEARCH PROTOCOL OF A PROSPECTIVE FOLLOW UP STUDY. <i>Psychiatria Danubina</i> , 2019, 31, 162-171.	0.4	8
9	<i>DPYD</i> polymorphisms <i>c.496A>G</i>, <i>c.2194G>A</i> and <i>c.85T>C</i> and risk of severe adverse drug reactions in patients treated with fluoropyrimidineâ€“based protocols. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2190-2202.	2.4	8
10	Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a caseâ€“control study. <i>European Journal of Clinical Pharmacology</i> , 2021, , 1.	1.9	7
11	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. <i>International Journal of Cardiology</i> , 2015, 186, 282-285.	1.7	6
12	Dapsoneâ€“induced agranulocytosisâ€“possible involvement of lowâ€“activity <i>N</i>-acetyltransferase 2. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 580-586.	1.9	6
13	Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. <i>Pharmacogenomics Journal</i> , 2020, 20, 638-646.	2.0	4
14	Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. <i>Croatian Medical Journal</i> , 2020, 61, 147-158.	0.7	4
15	Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 174-179.	1.9	3
16	Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2021, 72, 114-128.	0.7	2
17	Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, , .	1.5	2
18	The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: A longitudinal study. <i>Psychiatry Research</i> , 2019, 279, 389-390.	3.3	1